NYSE: ABBV · Life Sciences · 5 alerts · CIK 1551152
Share price
$294.55Close, Nov 16
Market cap
$521B
Shares outstanding
1.77BLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All AbbVie Inc. filings on SEC EDGAR ↗
AbbVie EVP, Chief Commercial Officer Jeffrey Ryan Stewart Sells $11.9M of Stock
Jeffrey Ryan Stewart, EVP, Chief Commercial Officer, sold 40,619 shares of AbbVie Inc. at $293.60 a share, worth $11.9M in total on Nov 9, 2026. Shares held after the trade: 83,171 (-32.8%).
Jennifer L. Davis, a Class II director, notified AbbVie of her intent to resign from the Board of Directors effective November 2, 2026. Her departure follows her appointment as CEO of Align Technology, Inc. and is not due to any disagreement with the company.
AbbVie reported third-quarter 2026 net revenues of $17.404 billion, a 10.3% increase driven by strong growth in its immunology and neuroscience portfolios. The company raised its full-year 2026 adjusted EPS guidance and announced a 5.2% increase to its quarterly dividend starting in February 2027.
Term
Q3 2026
“AbbVie continues to deliver outstanding results, reflecting solid execution across our diverse portfolio. We also enhanced our long-term growth potential by securing key regulatory approvals, generating differentiated clinical data and completing the acquisition of Apogee Therapeutics. Given our strong outlook and significant momentum, we are once again increasing AbbVie's full-year guidance and raising our quarterly dividend.”
Robert A. Michael, chairman and chief executive officer
AbbVie Inc. expanded its Board of Directors from twelve to thirteen members and appointed Dr. John M. Carethers as an independent Class II director. Dr. Carethers, who currently serves as Vice Chancellor for Health Sciences at UC San Diego, will also join the Board's Public Policy and Sustainability Committee.
AbbVie provided a preliminary update for Q3 2026, noting that results will include $216 million in acquired IPR&D and milestones expense, which negatively impacts EPS by $0.11. Consequently, the company updated its full-year 2026 adjusted diluted EPS guidance to a range of $13.76 - $13.96 and its Q3 guidance to $3.73 - $3.77.